| May 2026: |
|
| Wet AMD: new gene therapies.... |
|
| April 2025: |
|
| Acne vulgaris: time for something new.... |
|
| March 2025: |
|
| The industry's long suffering
COVID problem |
|
| May 2023: |
|
| Assessing the potential of new travel vaccines |
|
| March 2022: |
|
| A third of the major vaccine company pipeline is mRNA |
|
| November 2021: |
|
| Epstein-barr virus vaccines - preventing downstream risk |
|
| November 2020: |
|
| Seasonal influenza vaccines and the mRNA threat |
|
| August 2020: |
|
| The vaccine industry - filling the $2.5bn hole |
|
| June 2020: |
|
| Norovirus vaccines - rethinking market segments |
|
| June 2019: |
|
| A new Lyme disease vaccine - bravery to be rewarded |
|
| August 2018: |
|
| Pfizer's BioNTech influenza deal - the bold latecomer |
|
| July 2018: |
|
| A Lassa Fever vaccine - follow the footsteps of Ebola |
|
| February 2018: |
|
| FY 2017 vaccines sales data - major players [premium] |
|
| January 2018: |
|
| An opioid use disorder vaccine |
|
| November 2017: |
|
| 3Q vaccines sales data - major players |
|
| August 2017: |
|
| H1 (2Q) vaccines sales data - major players |
|
| May 2017: |
|
| Conference Report: 3rd ICVI London |
|
| April 2017: |
|
| 2016 FY results - the impact of real use and true product innovation. |
|
| February 2017: |
|
| Vaccines in the Trump era. |
|
| December 2016: |
|
| 2016 - year of the flavivirus vaccine. |
|
| November 2016: |
|
| 2017 places higher pressure on hospitals to avoid HAIs. |
|
| September 2016: |
|
| A Zika vaccine - the case strengthens. |
|
| May 2016: |
|
| The global influenza vaccine market - where next? |
|
| March 2016: |
|
| 2015 FY - Pfizer grows vaccine industry. |
|
| February 2016: |
|
| A Zika vaccine - late to the party we must attend |
|
| December 2015: |
|
| 2015 - The year of meningitis vaccines |
|
| August 2015: |
|
| 2015 Q2 - round up of results and R&D |
|
| May 2015: |
|
| Human metapneumovirus - why the poor cousin of RSV? |
|
| March 2015: |
|
| 2014 FY Results - vaccine industry, still bumping along. |
|
| December 2014: |
|
| Top ten vaccine industry events - 2015. |
|
| November 2014: |
|
| Influenza vaccines - more options but don't lose sight of longer term. |
|
| October 2014: |
|
| No room for blame after our surprise from Ebola. |
|
| September 2014: |
|
| 54th ICAAC, Washington DC conference - selective innovation won't do. |
|
| August 2014: |
|
| Pfizer vaccines boosts presence with low risk Baxter acquisitions. |
|
| June 2014: |
|
| Caribbean Chikungunya outbreak should move vaccine back onto the agenda. |
|
| April 2014: |
|
| Novartis to the vaccines industry - can we have our money back please? |
|
| March 2014: |
|
| Bexsero: good for UK children, Novartis Vaccines and a flat industry. |
|
| February 2014: |
|
| 2013 FY results - QIVs a highlight in a flat industry |
|
|
| December 2013: |
|
| Clostridium difficile vaccines: multipronged US-biased strategy to reduce economic burden. |
|
|
| November 2013: |
|
| Meningococcal group B vaccine, Bexsero: too late for the science? Stick to the wider economics |
|
|
| October 2013: |
|
| Who will benefit from the predicted boom in inactivated polio virus vaccines? |
|
|
| September 2013: |
|
| Middle East respiratory syndrome coronavirus (MERS-CoV) - worry, but dont panic. |
|
|
| August 2013: |
|
| Q2 2013 - Roundup of results and R&D |
|
|
| June 2013: |
|
| M&A in the vaccine sector. |
|
|
| March 2013: |
|
| PCSK9 mAbs or even vaccines - the new statins? |
|
|
| February 2013: |
|
| 2012 FY results - a flat industry poised for growth. |
|
|
| January 2013: |
|
| Protein Sciences FluBlok - finally here but much still to be done. |
|
|
| December 2012: |
|
| 2012 - another year for the vaccine industry. |
|
|
| October 2012: |
|
| Latest review of the vaccine R&D pipeline - Autumn 2012. |
|
|
| August 2012: |
|
| The vaccines industry: Q2 2012 round-up of results and R&D. |
|
|
| June 2012: |
|
| Quadrivalent influenza vaccines: full switch or niche position? |
|
|
| April 2012: |
|
| Is it still worth developing a Staph vaccine? |
|
|
| February 2012: |
|
| 2011 FY Results - vaccine industry waiting for next burst of growth. |
|
|
| January 2012: |
|
| A(H5N1), Avian influenza - still with us, ready to pounce? |
|
|
| November 2011: |
|
| Vaccine major players - Q3 round-up of results and R&D. |
|
|
| September 2011: |
|
| XVIII Lancefield International Symposium, Palermo, Sicily......vaccine update. |
|
|
| June 2011: |
|
| Melanoma vaccines - have Roche and BMS moved the goal posts? |
|
|
| May 2011: |
|
| New vaccines for dengue. Paying adults please. |
|
|
| March 2011: |
|
| 2010 FY Results. Its more than H1N1....... |
|
|
| January 2011: |
|
| The current industry landscape for therapeutic vaccines. |
|
|
| December 2010: |
|
| The vaccine industry in 2010 - highlights and lowlights. |
|
|
| November 2010: |
|
| How much is the current R&D vaccine pipeline worth? |
PREMIUM |
| Vaccine major players - Q3 round up of results and R&D |
|
|
| September 2010: |
|
| Discussing vaccines at the 50th ICAAC Boston. |
|
|
| August 2010: |
|
| Vaccine major players - Q2 round up of results and R&D |
|
| Considerations when commercial modelling a universal influenza vaccine. |
PREMIUM |
|
| June 2010: |
|
| A credible GBS vaccine - finally back on the agenda |
|
|
| May 2010: |
|
| Vaccine major players - Q1 round up of results and R&D |
|
|
| April 2010: |
|
| Healthcare acquired infections and vaccines - the profile determines everything. |
PREMIUM |
|
| March 2010: |
|
| Vaccines and Japanese Encephalitis - too early to call for Ixiaro? |
|
|
| February 2010: |
|
| The vaccine industry in 2009 - well past the $20 billion barrier. |
|
|
| January 2010: |
|
| H1N1 - boost to Novartis Vaccines, the industry but for how long? |
|
|
| December 2009: |
|
| 2009 and vaccines - lots of activity, and surprises. |
|
|
| November 2009: |
|
| New meningitis B vaccines - does the best science matter? |
PREMIUM |
| Rethinking new meningitis ACWY vaccines. |
|
| How to monitor fast moving vaccine R&D. |
|
|
October 2009: |
|
| New vaccine adjuvants - MPL paves the way. |
|
| H1N1 vaccines - the pros and cons of new technologies. |
|
|
| September 2009: |
|
| Vaccinating teenagers - growth platform. |
|
|
| August 2009: |
|
| Enterovirus-71: a long-term bet for the SE Asia region? |
PREMIUM |
| Latest vaccine R&D pipeline - flu sets agenda. |
|
|
| June 2009: |
|
| Chikungunya virus - should we think now about a vaccine? |
|
| Prevnar and PCV-13 versus Synflorix - waging war at 27th ESPID with antibody levels. |
PREMIUM |
|
| May 2009: |
|
| Major vaccine players - the race to Japan. |
|
| Modelling H1N1 vaccine demand - another multibillion dollar issue. |
|
|
| April 2009: |
|
Swine flu (H1N1) reminds us our flu vaccine technologies need updating. |
|
| GSKs Synflorix and Non-typeable H.influenzae - the secret to beating Wyeth? |
PREMIUM |
|
| March 2009: |
|
Pandemic flu - building the case to prime now. |
|
|
| February 2009: |
|
The vaccine industry - still growing, but more slowly. |
|
|
| January 2009: |
|
| GSK and Synflorix: closer to a different marketplace? |
PREMIUM |
| Wyeth and vaccines: first acquiring then acquired. |
|
| US Pandemic Planning Update VI - strong vaccine progress to date. |
|
